Neurocrine Biosciences 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): January 18, 2012
NEUROCRINE BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (858) 617-7600
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
In this report, Neurocrine, we, us and our refer to Neurocrine Biosciences, Inc.
The disclosure contained under the heading Year-End Cash and Investments on Exhibit 99.1 to this Form 8-K is incorporated herein by reference.
We are filing certain information for the purpose of updating aspects of the description of our business contained in our other filings with the Securities and Exchange Commission. A copy of this additional disclosure is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.